弥漫性内生性桥脑胶质瘤生存预测模型的外部验证:国际DIPG登记处与SIOPE DIPG登记处的协作报告
本研究对基于SIOPE DIPG登记处(荷兰、英国、德国患者)开发的DIPG生存预测模型进行外部验证,该模型以年龄<3岁、症状持续时间较长和接受化疗为有利预测因素,MRI环形强化为不利预测因素。使用国际DIPG登记处(美国、加拿大、澳大利亚、新西兰)未选择队列进行验证,评估判别与校准能力。结果显示模型具有可接受的跨队列校准,能区分短、平均和较长生存患者。
要点
- DIPG生存预测模型在外部验证队列中显示可接受的跨队列校准和判别能力。
- 验证队列Kaplan-Meier曲线重现标准风险(n=39)、中等风险(n=125)和高风险(n=78)三组。
- 校准曲线显示对预测生存概率存在对称性低估。
核心结论
- DIPG生存预测模型具有可接受的跨队列校准,能够区分短、平均和增加生存的患者。
研究设计与样本
- 外部验证研究,使用国际DIPG登记处未选择队列,包括来自美国、加拿大、澳大利亚和新西兰的患者。
主要发现
- 验证队列Kaplan-Meier曲线重现标准风险(n=39)、中等风险(n=125)和高风险(n=78)三组。
- 风险组间风险比数值相似,确认判别能力。
- 验证队列校准曲线显示对预测生存概率的对称性低估。
临床怎么用
- 作者讨论该临床-影像学模型可能在当前临床实践中发挥有用作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to perform external validation of the recently developed survival prediction model for diffuse intrinsic pontine glioma (DIPG), and discuss its utility. The DIPG survival prediction model was developed in a cohort of patients from the Netherlands, United Kingdom and Germany, registered in the SIOPE DIPG Registry, and includes age <3 years, longer symptom duration and receipt of chemotherapy as favorable predictors, and presence of ring-enhancement on MRI as unfavorable predictor. Model performance was evaluated by analyzing the discrimination and calibration abilities. External validation was performed using an unselected cohort from the International DIPG Registry, including patients from United States, Canada, Australia and New Zealand. Basic comparison with the results of the original study was performed using descriptive statistics, and univariate- and multivariable regression analyses in the validation cohort. External validation was assessed following a variety of analyses described previously. Baseline patient characteristics and results from the regression analyses were largely comparable. Kaplan-Meier curves of the validation cohort reproduced separated groups of standard (n = 39), intermediate (n = 125), and high-risk (n = 78) patients. This discriminative ability was confirmed by similar values for the hazard ratios across these risk groups. The calibration curve in the validation cohort showed a symmetric underestimation of the predicted survival probabilities. In this external validation study, we demonstrate that the DIPG survival prediction model has acceptable cross-cohort calibration and is able to discriminate patients with short, average, and increased survival. We discuss how this clinico-radiological model may serve a useful role in current clinical practice.
引用
- Veldhuijzen van Zanten SEM, Lane A, Heymans MW, et al. External validation of the diffuse intrinsic pontine glioma survival prediction model: a collaborative report from the International DIPG Registry and the SIOPE DIPG Registry. J Neurooncol. 2017. PMID: 28560664. doi:10.1007/s11060-017-2514-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。